Home » Archive

Drug Development

Drug Development, News, Syndication, Xconomy »

Rare FDA Ruling Triggers Stampede for Acadia Pharmaceuticals

Posted by sandiegobiotech April 11th, 2013 .
No Comments

How often does the FDA tell a drug developer to dispense with a requisite, second late-stage trial—and to proceed with filing a new drug application? Shares of San Diego’s Acadia…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

Rare FDA Ruling Triggers Stampede for Acadia Pharmaceuticals

Posted by sandiegobiotech April 11th, 2013 .
No Comments

How often does the FDA tell a drug developer to dispense with a requisite, second late-stage trial—and to proceed with filing a new drug application? Shares of San Diego’s Acadia…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

Rare FDA Ruling Triggers Stampede for Acadia Pharmaceuticals

Posted by sandiegobiotech April 11th, 2013 .
No Comments

How often does the FDA tell a drug developer to dispense with a requisite, second late-stage trial—and to proceed with filing a new drug application? Shares of San Diego’s Acadia…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

San Diego’s Ambrx Working with Astellas to Develop Anti-Cancer Drugs

Posted by sandiegobiotech April 8th, 2013 .
No Comments

San Diego-based Ambrx says it’s getting an upfront payment of $15 million under a deal with Japan’s Astellas to help develop an undisclosed number of targets for antibody drug conjugates in cancer….

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

Still Waiting for the Ships to Come in at Third Rock Ventures

Posted by sandiegobiotech March 28th, 2013 .
No Comments

Third Rock Ventures was in the enviable position of turning away some institutional investors when the life sciences venture firm recently closed on $516 million for its third venture fund. So first…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

New Domain Partnership Focuses on China’s Emerging Healthcare Market

Posted by sandiegobiotech March 13th, 2013 .
No Comments

Domain Associates, the life sciences venture firm based in San Diego and Princeton, NJ, says today it has formed a partnership with the Beijing-based firm Elite Consulting to license biomedical…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

Sophiris Bio Files $75M IPO, Plans Pivotal Trials of Prostate Drug

Posted by sandiegobiotech February 19th, 2013 .
No Comments

San Diego-based Sophiris Bio, which was founded in Vancouver B.C. and already trades on the Toronto Stock Exchange, intends to list its shares on the Nasdaq and raise almost $75 million through an…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

Elcelyx Closes on $20M to Advance Appetite-Control Compounds

Posted by sandiegobiotech February 14th, 2013 .
No Comments

It’s Valentine’s Day, and San Diego’s Elcelyx Therapeutics is feeling the love. The startup, focused on obesity and diabetes, says today it has closed on $20 million in Series C financing led by the…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

California Stem Cell Agency Shifts Focus to Clinical Treatments

Posted by sandiegobiotech January 31st, 2013 .
No Comments

California’s stem cell research funding agency has been shifting gears, and California entrepreneurs stand to benefit. The California Institute for Regenerative Medicine (CIRM) plans to spend…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

FDA OKs First-in-Class Drug From Isis for Rare Cholesterol Disorder

Posted by sandiegobiotech January 29th, 2013 .
No Comments

The FDA today approved the cholesterol-lowering drug mipomersen (Kynamro)—the first major RNA therapeutic developed by Carlsbad, CA-based Isis Pharmaceuticals (NASDAQ: ISIS). Isis has been developing…

[[Click headline to continue reading.]]

More...